Literature DB >> 30171046

A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.

Julia Hess1,2, Kristian Unger3,2, Michael Henke4,5, Claus Belka2,6,7, Cornelius Maihoefer2,6, Lars Schüttrumpf2,6, Ludmila Wintergerst3,2, Theresa Heider3,2, Peter Weber3,2,8,9, Sebastian Marschner2,6, Herbert Braselmann3,2, Daniel Samaga3,2, Sebastian Kuger3, Ulrike Pflugradt2,6, Philipp Baumeister2,10, Axel Walch11, Christine Woischke12, Thomas Kirchner12,7, Martin Werner13,14,4, Kristin Werner13,14,4, Michael Baumann15, Volker Budach16,17, Stephanie E Combs7,18,19, Jürgen Debus20,21, Anca-Ligia Grosu4,5, Mechthild Krause15,22,23,24, Annett Linge15,22,23,24,25, Claus Rödel26,27, Martin Stuschke28,29, Daniel Zips30,31, Horst Zitzelsberger3,2,6, Ute Ganswindt2,6,32.   

Abstract

PURPOSE: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is associated with unfavorable prognosis, while independent prognostic markers remain to be defined. EXPERIMENTAL
DESIGN: We retrospectively performed miRNA expression profiling. Patients were operated for locally advanced HPV-negative HNSCC and had received radiochemotherapy in eight different hospitals (DKTK-ROG; n = 85). Selection fulfilled comparable demographic, treatment, and follow-up characteristics. Findings were validated in an independent single-center patient sample (LMU-KKG; n = 77). A prognostic miRNA signature was developed for freedom from recurrence and tested for other endpoints. Recursive-partitioning analysis was performed on the miRNA signature, tumor and nodal stage, and extracapsular nodal spread. Technical validation used qRT-PCR. An miRNA-mRNA target network was generated and analyzed.
RESULTS: For DKTK-ROG and LMU-KKG patients, the median follow-up was 5.1 and 5.3 years, and the 5-year freedom from recurrence rate was 63.5% and 75.3%, respectively. A five-miRNA signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306, and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG [hazard ratio (HR) 4.42; 95% confidence interval (CI), 1.98-9.88, P < 0.001], which was confirmed in LMU-KKG (HR 4.24; 95% CI, 1.40-12.81, P = 0.005). The signature also predicted overall survival (HR 3.03; 95% CI, 1.50-6.12, P = 0.001), recurrence-free survival (HR 3.16; 95% CI, 1.65-6.04, P < 0.001), and disease-specific survival (HR 5.12; 95% CI, 1.88-13.92, P < 0.001), all confirmed in LMU-KKG data. Adjustment for relevant covariates maintained the miRNA signature predicting all endpoints. Recursive-partitioning analysis of both samples combined classified patients into low (n = 17), low-intermediate (n = 80), high-intermediate (n = 48), or high risk (n = 17) for recurrence (P < 0.001).
CONCLUSIONS: The five-miRNA signature is a strong and independent prognostic factor for disease recurrence and survival of patients with HPV-negative HNSCC.See related commentary by Clump et al., p. 1441. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30171046     DOI: 10.1158/1078-0432.CCR-18-0776

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

Review 1.  Multiple microRNA signature panel as promising potential for diagnosis and prognosis of head and neck cancer.

Authors:  Sethu Thakachy Subha; Yoke Kqueen Cheah; Jun Wei Chin; Norhafizah Mohtarrudin; Hasni Idayu Saidi
Journal:  Mol Biol Rep       Date:  2021-11-27       Impact factor: 2.316

2.  Autophagy-Related Signature for Head and Neck Squamous Cell Carcinoma.

Authors:  Cheng Li; Zeng-Hong Wu; Kun Yuan
Journal:  Dis Markers       Date:  2020-10-19       Impact factor: 3.434

3.  Screening for microRNA-based diagnostic markers in hepatic alveolar echinococcosis.

Authors:  Bin Ren; Haijiu Wang; Li Ren; Cairang Yangdan; Ying Zhou; Haining Fan; Yi Lv
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 4.  Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.

Authors:  Takashi Takeuchi; Hiromichi Kawasaki; Amalia Luce; Alessia Maria Cossu; Gabriella Misso; Marianna Scrima; Marco Bocchetti; Filippo Ricciardiello; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

5.  Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.

Authors:  Wei Huang; Yi-Guo Yan; Wen-Jun Wang; Zhi-Hua Ouyang; Xue-Lin Li; Tao-Lan Zhang; Xiao-Bin Wang; Bing Wang; Guo-Hua Lv; Jing Li; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

Review 6.  X-change symposium: status and future of modern radiation oncology-from technology to biology.

Authors:  Stefanie Corradini; Maximilian Niyazi; Dirk Verellen; Vincenzo Valentini; Seán Walsh; Anca-L Grosu; Kirsten Lauber; Amato Giaccia; Kristian Unger; Jürgen Debus; Bradley R Pieters; Matthias Guckenberger; Suresh Senan; Wilfried Budach; Roland Rad; Julia Mayerle; Claus Belka
Journal:  Radiat Oncol       Date:  2021-02-04       Impact factor: 4.309

7.  Long noncoding RNA ILF3-AS1 aggravates papillary thyroid carcinoma progression via regulating the miR-4306/PLAGL2 axis.

Authors:  Zhaohui Zeng; Qiangfeng Teng; Jinhong Xiao
Journal:  Cancer Cell Int       Date:  2021-06-27       Impact factor: 5.722

8.  Single-center versus multi-center data sets for molecular prognostic modeling: a simulation study.

Authors:  Daniel Samaga; Roman Hornung; Herbert Braselmann; Julia Hess; Horst Zitzelsberger; Claus Belka; Anne-Laure Boulesteix; Kristian Unger
Journal:  Radiat Oncol       Date:  2020-05-14       Impact factor: 3.481

Review 9.  Exosomes in Head and Neck Squamous Cell Carcinoma.

Authors:  Cheng Xiao; Fang Song; Yu Long Zheng; Jiong Lv; Qiang Feng Wang; Nong Xu
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

10.  Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".

Authors:  Lars Schüttrumpf; Sebastian Marschner; Katrin Scheu; Julia Hess; Sibylle Rietzler; Axel Walch; Philipp Baumeister; Thomas Kirchner; Ute Ganswindt; Horst Zitzelsberger; Claus Belka; Cornelius Maihoefer
Journal:  Radiat Oncol       Date:  2020-01-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.